Hydroxychloroquine and Nifekalant added to Known Risk of TdP

The class III antiarrhythmic agent, nifekalant, (marketed in Japan) has been added to the Known Risk of Torsades de Pointes (TdP) list because of evidence that its use is associated with TdP.  Also, the antimalarial drug hydroxychloroquine has been moved from the Conditional Risk of TdP list to the Known Risk of TdP list because we have found evidence of TdP, even when used as directed.

We welcome your feedback and suggestions for how CredibleMeds can better serve your need for information about medicines.